Chemring closes at 7.2 ahead of announcement of U.S. sensor business sale
Key Facts
Chemring shares, listed under the ticker CMGMF, closed at 7.2 on 17 November 2026, according to EL7 data, with no currency specified in the price record. The company announced on 12 November that it had begun a sale process for Chemring Sensors and Electronic Systems, known as CSES, following a strategic review. Chemring said the board had decided to launch the process, without citing a target price or timetable for completing the sale. The decision puts a specific U.S. business on a divestment path, while the company’s announcement made no reference to a broader group restructuring. It comes ahead of the announcement of results for the financial year ended 31 October 2026, scheduled for 8 December.
Chemring said CSES holds a strong market position as the sole supplier of biological warfare agent detectors to the U.S. Department of Defense. That description gives the business a direct link to a U.S. government agency, but the company’s statement does not specify the business’s value or the terms of a potential sale. CSES forms part of the Sensors & Information segment, one of the two strategic segments into which Chemring says the group is organized. The other segment is Countermeasures & Energetics, which represents a parallel strategic area within the group. The 12 November announcement therefore concerns the sale process for one business, within a stated structure based on two product segments.
First-half fiscal 2026 results showed revenue growth alongside a decline in underlying operating profit. Revenue was £237.3 million in the six months ended 30 April 2026, up 7% from £222.8 million in the corresponding period of 2025. By contrast, underlying operating profit fell 8% to £24.5 million, compared with £26.5 million a year earlier. The figures present a mixed picture for the period: revenue expanded while underlying operating profit declined. The CSES sale announcement does not say how the process, if completed, would affect the group’s results or the distribution of its businesses between the two segments.
Chemring said Roke’s performance in fiscal 2026 was below expectations because of delays in awarding defense contracts, particularly those linked to the UK Ministry of Defence. Chief Executive Michael Ord said the programs in question remained active opportunities despite the delays in contract awards. At the same time, the board maintained its expectation of year-on-year earnings growth in fiscal 2027, citing the order book scheduled for delivery during the year. The order book reached a record £1.4 billion on 31 October 2026, compared with £1.3 billion on 31 October 2025. This provides context for management’s outlook, while the operational challenge related to the timing of contract awards at Roke remains.
The company’s announcements included new contracts in the UK and the United States. In the UK, Chemring announced a seven-year exclusive framework with the Ministry of Defence worth up to £100 million, alongside an initial production contract worth £23 million, with deliveries due to begin in 2027. It also said Roke had signed a five-year strategic partnership agreement with a major U.S. contractor, with an expected value of at least $170 million, including an initial production order worth $16 million. These contracts support the volume of work scheduled for execution, while their actual contribution depends on delivery and execution schedules. Chemring estimated underlying operating profit for fiscal 2026 at about £79 million and said it had generated more than £50 million in the second half.
Chemring is scheduled to publish results for the year ended 31 October 2026 on 8 December, the next date specified in its announcement. The results will provide an updated view of the year’s financial and operational performance, as the company expects year-on-year earnings growth in fiscal 2027. Management linked that outlook to the order book scheduled for delivery during the year, which stood at £1.4 billion at the end of October. The CSES sale process also remains a separate initiative launched by the company after a strategic review, and its announcement did not specify the transaction’s value or completion timing. The company’s published statement does not confirm information about an investment stake held by Palliser Capital or pressure from the fund to break up the group.